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(Communicated by Tasuku HONJO, M.J.A.)
Abstract: In this review, the author discusses the research that led to the identiﬁcation and
characterization of interleukin 6 (IL-6), including his own experience isolating IL-6, and the roles
this cytokine has on autoimmune and inﬂammatory diseases. The cDNAs encoding B-cell
stimulatory factor 2 (BSF-2), interferon (IFN)--2 and a 26-kDa protein were independently cloned
in 1986, which in turn led to the identiﬁcation of each. To resolve the confusing nomenclature, these
identical molecules were named IL-6. Characterization of IL-6 revealed a multifunctional cytokine
that is involved in not only immune responses but also hematopoiesis, inﬂammation, and bone
metabolism. Moreover, IL-6 makes signiﬁcant contributions to such autoimmune and inﬂammatory
diseases as rheumatoid arthritis (RA).
IL-6 activates both the STAT3 and SHP2/Gab/MAPK signaling pathways via the gp130
signal transducer. F759 mice, which contain a single amino-acid substitution in gp130 (Y759F) and
show enhanced STAT3 activation, spontaneously develop a RA-like arthritis as they age. F759
arthritis is dependent on CD4+ T cells, IL-6, and IL-17A, and is enhanced by the pX gene product
from human T cell leukemia virus 1 (HTLV-1). Arthritis development in these mice requires that
the F759 mutation is present in nonhematopoietic cells, but not in immune cells, highlighting the
important role of the interaction between nonimmune tissues and the immune system in this
disease. Furthermore, this interaction is mediated by the IL-6 ampliﬁer through STAT3 and NF-
5B. Ultimately, this model may represent a general etiologic process underlying other autoimmune
and inﬂammatory diseases. More importantly, the understanding of IL-6 has paved the way for new
therapeutic approaches for RA and other autoimmune and inﬂammatory diseases.
Keywords: cytokine, Interleukin 6, immune response, inﬂammation, autoimmune disease,
rheumatoid arthritis
Introduction
The immune system is essential for human
survival, as it recognizes and eliminates viruses,
bacteria, and other infectious pathogens. At times,
however, immune responses can be deleterious to
human beings. For example, autoimmune diseases—
RA, systemic lupus erythematosus, type 1 diabetes
mellitus, Graves’ disease, and multiple sclerosis,
among others—develop when the immune system
attacks the host’s own tissues, resulting in a self-
destructive process. Therefore, the immune system
can be a double-edged sword.
Autoimmune diseases comprise a heterogeneous
group of poorly understood disorders, the pathogen-
eses of which involve both genetic and environmental
factors.1)–4) These diseases are generally classiﬁed
into two major types: tissue-speciﬁc and systemic.
Some autoimmune diseases are mediated by patho-
genic and tissue-speciﬁc autoantibodies, resulting in
localized eﬀects in speciﬁcally targeted organs. In
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multiple organ systems. In both cases, disease
initiation is thought to result from a breakdown in
self-tolerance, particularly when a well-deﬁned
pathogenic autoantigen has been identiﬁed and the
disease speciﬁcally manifests in tissues that express
the autoantigen. Interestingly, however, pathogenic
antigens have not been identiﬁed for many auto-
immune diseases, including RA and other tissue-
speciﬁc disorders.5),6) This raises the possibility that a
breakdown in tolerance to a tissue-speciﬁc antigen is
not always required for localized autoimmune dis-
eases. Rather, in certain diseases, the etiologic trigger
may be a characteristic of the target tissue itself.
In other words, aberrant activation of the immune
system may be a consequence of events that are
initiated by an inﬂammatory niche in a nonimmune
target tissue in response to genetic and/or environ-
mental factors.1),7)–10)
Major immune cell populations include T
lymphocytes, B lymphocytes, macrophages, and
antigen-presenting dendritic cells. These cells inter-
act with each other to initiate immune responses
against pathogens and, at times, the human body
itself. Cytokines, such as interleukins and IFNs, are
soluble factors produced by a variety of immune cells.
These factors play crucial roles in immune responses,
as abnormal cytokine production and activity are
involved in several autoimmune and inﬂammatory
diseases.3),7),11)–14) Importantly, clinical research has
revealed that inhibitors of certain cytokines are
beneﬁcial to certain patients suﬀering from auto-
immune or inﬂammatory diseases like RA.15)–17)
IL-6 is a pleiotropic cytokine that regulates
multiple biological processes, including the develop-
ment of the nervous and hematopoietic systems,
acute-phase responses, inﬂammation, and immune
responses.7) Patients with RA show high synovial
concentrations of IL-6.11) Recent reports have high-
lighted the important roles of proinﬂammatory
cytokines, such as TNF-,, IL-1, and IL-6, in the
pathogenesis of RA.12)–14) IL-6 also contributes to the
model of spontaneously occurring RA observed in
F759 mice and SKG mice, and in antigen-induced RA
models, such as collagen-induced arthritis and
adjuvant-induced arthritis.18)–22) Furthermore, some
patients with RA respond to treatment with anti–IL-
6 receptor antibodies.16),17) Nine IL-6 family cyto-
kines have been identiﬁed, including IL-6, oncostatin
M, LIF, CNTF, CT-1, IL-11, and IL-27.23),24) All of
these signaling molecules share gp130 as a receptor
subunit and signal transducer. It has been established
that gp130 is involved in two major signaling
pathways: the JAK–signal transducer and activator
of transcription 3 (STAT3) pathway, which is
mediated by the YxxQ motif of gp130, and the
SHP2–Gab-Ras-Erk–MAPK pathway, which is regu-
lated via the cytoplasmic Y759 residue of gp130.24)–26)
Importantly, F759 mice, which show enhanced
STAT3 activation via gp130, a signal transducer of
IL-6 family cytokines, spontaneously develop RA-like
arthritis.18),24)
Recently, the in vivo roles of IL-6 in T cell
functioning have been reconsidered, because this
molecule is involved in interactions between two
critical CD4+ T cell populations: regulatory T (Treg)
cells and T helper 17 (Th17) cells. Of note, Th17 cells
secrete several proinﬂammatory cytokines, such as
IL-17, and contribute to the induction of various
chronic inﬂammatory conditions, including auto-
immune diseases. Interestingly, T cell receptor
(TCR)-induced development of Foxp3+CD4+ T cells
requires TGF--, whereas IL-6–mediated signaling via
STAT3 suppresses the development of this popula-
tion while increasing the number of Th17 cells by
enhancing ROR.t expression.27)–33) On the other
hand, maturation of natural thymus-derived
Foxp3+CD4+ T cells in vivo is not aﬀected by IL-6–
mediated signaling under steady state.34) Further,
follicular helper T cells, which have recently emerged
as a separate CD4+ T helper lineage that speciﬁcally
supports B cell activities, diﬀerentiate from naïve
CD4+ T cells in the presence of IL-6 via Bcl6
expression.35) Thus, IL-6 is involved in fate control-
ling of cytokine secreting CD4+ T cells, which play a
role in the development of autoimmune diseases.
Cytokines in the 1970s
When the author graduated from Osaka Uni-
versity Medical School in 1972, it was known that
interactions among immune cells, such as T lympho-
cytes, B lymphocytes, and macrophages, are required
for immune responses. Studies had shown that
antigenic stimulation causes immune cells to produce
several soluble factors, which we now call cytokines,
and that these soluble factors are required for a range
of immune responses. For example, antigens in the
presence of T lymphocytes induce the diﬀerentiation
of B lymphocytes into immunoglobulin-producing
plasma cells. In 1971 and 1972, Richard W. Dutton,
Anneliese Schimpl, and Eberhard Wecker reported
the presence of soluble factors that induced immu-
noglobulin production in B cells.36),37) The molecular
characteristics of these soluble factors, however, were
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each factor by a diﬀerent name based on the
biological activity the investigator was examining;
thus, at times, it appeared as if each factor had as
many aliases as there were immunologists. At that
time, I was interested in characterizing the molecular
nature of soluble factors that acted on B cells. In
1973, I applied for a visiting fellowship at the United
States National Institutes of Health, and joined Dr.
Albert A. Nordin’s immunology laboratory at The
Gerontology Research Center (now called The Na-
tional Institute on Aging). There in Baltimore, I ﬁrst
met Dr. Tadamitsu Kishimoto and Dr. Kiyoshi
Takatsu, both of whom were members of Dr.
Kimishige Ishizaka’s laboratory at John Hopkins
University and have since taught me a great deal.
After spending three years in Dr. Nordin’s laboratory
researching cytotoxic T cell diﬀerentiation and the
soluble factors involved, I returned to Osaka Uni-
versity Medical School in 1976 and two years later
moved to Osaka Prefectural Habikino Hospital, now
the Osaka Prefectural Medical Center for Respira-
tory and Allergic Diseases, where I saw a number of
patients with tuberculous pleurisy.
A steep climb leading to the discovery of IL-6
The research I was conducting there demon-
strated that puriﬁed protein derivative (PPD)-
stimulated pleural eﬀusion cells from patients with
pulmonary tuberculosis produced soluble factors
capable of inducing immunoglobulin production in
B cells (Fig. 1).38) Because this activity appeared to
be very robust and a large number of lymphocytes
could be obtained from each patient (up to
1×1 0 9cells/patient), I decided to isolate the active
factor and began to devise a puriﬁcation protocol in
1978. In early 1980, Muraguchi, Kishimoto, and their
colleagues,39) as well as Teranishi, myself, and our
colleagues40) independently showed that culture
supernatant fractions from stimulated human pe-
ripheral blood mononuclear cells and tonsillar mono-
nuclear cells, respectively, induce immunoglobulin
production in Epstein-Barr virus–transformed B
lymphoblastoid cell lines. Kishimoto’s group called
this factor “TRF” or “BCDF”,39),41) whereas our group
called it “TRF-like factor” or “BCDFII”.40),42),43) We
partially puriﬁed the TRF-like factor and showed
that it was present in gel ﬁltration fractions
corresponding to molecular weights of 22kDa and
36kDa, and that its isoelectric point was between 5
and 6 (Fig. 1).40) The biological activity and phys-
icochemical properties of the soluble factor were the
same as those of a cytokine, now known as IL-6.7)
I moved to Kumamoto University Medical School in
1980 as an Associate Professor in Dr. Onoue’s
laboratory where I continued my eﬀorts to purify
and characterize this factor. In early 1984, I began
working at Osaka University as an Associate
Professor in Dr. Kishimoto’s laboratory and by the
end of the year, ﬁnally succeeded in purifying the
factor and determining the sequence of its 14 N-
terminal amino acids.44),45) This success allowed me a
brief reprieve from my work just before the new year.
The next steps, however, were much harder than I
expected. Several attempts to clone cDNA encoding
the active protein completely failed. This raised the
possibility that the identiﬁed sequence may have
been incorrect or may have represented other
proteins that had been co-puriﬁed with the active
molecule. These worries gave me serious ill including
a severe arrhythmia and kept me up at night through
to the end of 1985. Thankfully, a medical checkup
showed that my arrhythmia was psychogenic. I then
attempted to purify the protein using 100 liters of
newly obtained culture supernatants. We were lucky
enough to obtain several protein fragments and their
partial amino-acid sequences in March, 1986. Then,
to clone the cDNA, we used three probes correspond-
ing to three puriﬁed protein fragments. I speculated
that this approach was more likely to succeed than
using only one probe that corresponded to the N-
terminal portion of the protein.
Standing atop the mountain: Isolation of IL-6
After 8 years of eﬀort, my goal suddenly came
into view. At 11 am on Sunday morning, May 25th,
1986, I found a clone that was bound by all three
probes. It was no longer a dream; it was a reality.
I was very conﬁdent that we had ﬁnally cloned a
cDNA encoding the active protein, which we called
“BSF-2” at that time and had previously called
BCDF, BCDFII, or TRF-like factor. The sequence of
the cDNA showed that BSF-2 is synthesized as a
precursor consisting of 212 amino acids and is
processed into a mature form consisting of 184 amino
acids. From the molecular weight, isoelectric point
and its induction of immunoglobulin production in an
Epstein-Barr virus transformed B cell line, it was
likely that BSF-2 was in fact the same molecule as
the TRF-like factor that we had been analyzing. We
published our results in a November 1986 issue of
Nature.46) To my surprise, the sequence we reported
was identical to that of an IL-1–induced 26-kDa
protein reported by Robert Hageman and Walter
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of Biochemistry47) and that of IFN--2 reported by
Asher Zilberstein and Michel Revel in the October
issue of The EMBO Journal.48) A January 1988 issue
of Science reported that an orphan interferon had
found a new home.49) Uncertainties about the roles of
IFN--2 were being resolved as researchers found that
it has numerous activities in the body’s defenses.50)
Furthermore, plasmacytoma/hybridoma/myeloma
growth factor and hepatocyte-stimulating factor,
which regulates the biosynthesis of a variety of
acute-phase proteins, were also found to be identical
to this factor.51)–55) To resolve these nomenclature
issues, Dr. William E. Paul chaired a nomenclature
meeting in New York City on December 14, 1988, at
which the name “interleukin-6” was proposed
(Fig. 2).56) It is worth noting that two important
molecules acting on B cells, IL-4 and IL-5 were also
cloned in 1986.57),58)
I had wished to isolate the factor that stimulates
B cells to produce immunoglobulin. Once we cloned
the factor, however, it was clear that IL-6 acts on a
variety of cells and tissues in addition to B cells. For
instance, IL-6 induces hepatocytes to express various
acute-phase proteins; activates osteoclasts to destroy
bone tissue; functions as a growth factor for myeloma
Preparative isoelectric focusing
1 X 106 cells/ml
20 µ µg/ml PPD
at 37°C for 48 hr
Fig. 1. PPD-stimulated pleural eﬀusion cells produce soluble factors capable of inducing immunoglobulin production in B cells. The
culture supernatant from the pleural eﬀusion cells or tonsillar mononuclear cells contained an active factor that had the same biologic
and physicochemical properties of the cytokine now known as IL-6.
T. HIRANO [Vol. 86, 720and plasmacytoma cells; increases platelet produc-
tion; and precipitates fever and cachexia. IL-6 is
therefore a multifunctional cytokine that plays
roles in immune responses, inﬂammation, hemato-
poiesis, and the endocrine and nervous systems
(Fig. 3).7),59)–61)
After IL-6 was cloned, we isolated its receptor
in the late 1980s. In fact, we cloned a cDNA
encoding the IL-6 receptor using expression cloning,
which had just been introduced by Brian Seed and
his colleagues.62) Then, we cloned the signal-trans-
ducing receptor subunit gp130,63),64) demonstrating
that the IL-6 receptor comprises an IL-6–speciﬁc
alpha chain subunit and the gp130 signal trans-
ducer (Fig. 4). Interestingly, gp130 functions not
only as a receptor subunit for IL-6, but also as
Fig. 2. At a nomenclature meeting chaired by Dr. W. E. Paul, the name “interleukin-6” was proposed for these synonymous molecules
(Dec. 14, 1988; New York).56)
Fig. 3. Multifunctional cytokine IL-6 is produced by a variety of cell types, including T cells, B cells, macrophages, astrocytes, stromal
cells, vascular endothelial cells, smooth muscle cells, and ﬁbroblasts. IL-6 induces antibody expression (B cell stimulatory factor 2) and
cytotoxic T-lymphocyte activity (T cell activation factor). IL-6 was also referred to as a hybridoma/plasmacytoma growth factor and
a hepatocyte stimulatory factor. IL-6 acts as a growth factor for AIDS-related Kaposi’s sarcoma, mesangial cells, and renal cell
carcinomas, and as a thrombopoietin, a nerve growth factor, a hormone-inducing factor in the pituitary gland, an osteoclast-inducing
factor, and a keratinocyte growth factor.
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IL-11, OSM, LIF, CT-1, CNTF, and IL-27
(Fig. 5).23),24) Although the results had already
exceeded my expectations, this was not the end
of the story.
The view from the mountaintop: IL-6 is critically
involved in autoimmune diseases, including RA
Patients with cardiac myxoma show a variety of
autoimmune symptoms, such as hypergammaglobu-
linemia, the presence of autoantibodies, and increas-
ed acute-phase protein levels. Each of these symp-
toms is ameliorated when the tumor cells are
resected, suggesting that cardiac myxoma cells
induce autoimmunity. We found that cardiac myx-
oma cells produce IL-6,45) providing the ﬁrst evidence
of a role for IL-6 in an autoimmune disease. We then
found that patients with RA have high synovial
levels of IL-6 (Fig. 6),11) suggesting, for the ﬁrst time,
that IL-6 is involved in RA, a chronic autoimmune
polyarthritis. Although both genetic and environ-
mental factors contribute to this disease, the speciﬁc
etiology is unknown. Patients with RA show a
variety of symptoms, including polyclonal plasmacy-
tosis accompanied by the production of rheumatoid
factor, increased levels of acute-phase proteins,
enhanced bone resorption, and increased platelet
numbers, all of which do not at ﬁrst glance appear
closely related. The pleiotropic nature of IL-6,
however, may shed some light on this puzzle. I
speculated that dysregulation of IL-6 gene expression
or activity is intimately related to the development of
RA.7),65)
In the early 1990s, after being appointed
Professor at the Osaka University Medical School, I
proposed a working hypothesis for the mechanisms
that underlie chronic inﬂammatory proliferative
disease (CIPD) and certain autoimmune diseases in
which IL-6 is thought to play a role.7),65) In the
model, constitutive activation of a set of tran-
scription factors—for example, NF-5B—critically
governs the onset and progression of these diseases
(Fig. 7). During the initial phase, inﬂammation and
transcription factor activation can be induced by a
variety of stimuli, including infection, foreign materi-
Fig. 4. IL-6 receptor is composed of two subunits: an IL-6–
speciﬁc alpha chain subunit and the signal transducer gp130.
IL-11Rα α
IL-6 IL-11 mOSM LIF hOSM
CNTFRα
CNTF CRLF1
CLCF1
CT-1
CT-1Rα?
mCT-2
IL-6Rα
IL-27 IL-31
gp130 gp130 gp130 gp130 gp130 gp130 gp130-like
OSMRβ LIFRβ LIFRβ LIFRβ WSX1 OSMRβ gp130
gp130
gp130
Fig. 5. gp130 is not only a receptor subunit for IL-6, but also functions as a signal transducer for other cytokines like IL-11, OSM, LIF,
CT-1, CNTF, and IL-27.
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and other cytokines, MHC molecules, adhesion
molecules, autoantigens, and transcription factors.
In the context of MHC molecules, autoantigens may
then be recognized by autoreactive T cells, activat-
ing the T cells to propagate the inﬂammatory
response. Because the ﬁrst phase could occur in
nonimmune cells or tissues, this model implies that
interactions between nonimmune and immune sys-
tems may play critical roles in autoimmune diseases
and CIPD.
To understand the molecular networks regulated
by IL-6, we investigated IL-6 receptor–related signal
transduction pathways. We showed that IL-6 induces
two major signal transduction pathways: STAT3
and SHP2/Gab/MAPK signaling, which involve
the gp130 YxxQ and Y759 motives, respectively
(Fig. 8).24),25) We then attempted to clarify the in
vivo roles of each of these gp130-associated signaling
cascades. We generated a series of knock-in mouse
lines in which gp130-mediated SHP2 or STAT3
signaling was selectively disrupted.26) To create
SHP2 signal–deﬁcient mice (F759 mice), we mutated
Y759 of gp130 to a phenylalanine residue. F759 mice
show enhanced STAT3 activation through gp130
because Y759 is required for SOCS3-mediated
negative feedback mechanisms. The most intriguing
ﬁnding was that F759 mice spontaneously develop a
RA-like joint disease (F759 arthritis) (Fig. 9).18) This
was the ﬁrst deﬁnitive evidence that showed a critical
role for IL-6 in a spontaneous autoimmune disease.
Interestingly, like RA, F759 arthritis is a late onset
disease, characterized by a symmetrical and pro-
gressive presentation. F759 mice show a variety of
Fig. 6. High levels of IL-6 are present in the synovial ﬂuids of RA
patients.11) OA, osteoarthritis.
Fig. 7. A working hypothesis for the mechanisms involved in certain autoimmune diseases and CIPD. During the initial phase,
inﬂammation and transcription factor activation can be induced by a variety of stimuli, including infection, foreign materials, and/or
injury, leading to the expression of IL-6 and other cytokines, MHC molecules, adhesion molecules, autoantigens, and transcription
factors. Autoantigens in the context of MHC molecules may be recognized by autoreactive T cells, activating the T cells to propagate
the inﬂammatory response. Because the ﬁrst phase can occur in nonimmune cells or tissues, this model implies that interactions
between nonimmune and the immune systems may play critical roles in autoimmune diseases and CIPD.
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maglobulinemia, autoantibody production, and an
increased number of memory activated T cells. These
eﬀects result from a point mutation in gp130, leading
to enhanced STAT3 activation by IL-6. We then
asked whether HTLV-1 infection serves as an environ-
mental trigger for F759 arthritis. Iwakura and his
colleagues had shown that HTLV-1 pX transgenic
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y759
Y
STAT3
SHP2
Y GAB
PI3K
Y Y
SHP2
MAPK
Growth Differentiation Movement Survival
IL-6
gp130 gp130 α α α
P
JAK Y JAK Y
YXXQ
Fig. 8. IL-6 induces two major signal transduction pathways, STAT3 signaling and SHP2/Gab/MAPK signaling. Activation of these
pathways depends on the gp130 YxxQ motives and Y759, respectively.
Y767
Y814
Y905
Y915
P-STAT3 
ERK MAPK
SHP-2
F759 mouse 
Increase in the numbers of memory/activated T cells, 
granulocytes, and plasma cells
Splenomegaly & lymphadenopathy
Hypergammaglobulinemia
Autoantibodies (RF, ss-DNA, ds-DNA, nRNP) 
Dendritic cells show an immature phenotype.
Resistance to SEB-induced peripheral clonal deletion.
Mature lymphocytes are required for the disease.
Arthritis
Symmetrical, chronic and progressive
Late onset (Around 10 months)
High incidence (~100%)
Predominant infiltration of neutrophils
Hyperplasia of synovial fibroblasts
Joint destruction and ankylosis
Pannus formation and activated osteoclasts
SOCS3
->F
Fig. 9. F759 mice show enhanced STAT3 activation in response to IL-6 owing to the Y759F mutation in gp130, which inhibits SOCS3-
mediated negative feedback. These mutant mice spontaneously develop a RA-like joint disease (F759 arthritis). Characteristics of the
disease are included in the ﬁgure: late onset; nearly 100% incidence; symmetrical, chronic, and progressive symptoms; inﬁltration of
neutrophils into the joints; hyperplasia of synovial ﬁbroblasts; pannus formation and the presence of activated osteoclasts; joint
destruction and ankylosis; splenomegaly and lymphadenopathy; hypergammaglobulinemia; autoantibody productions; increased
numbers of memory/activated T cells, granulocytes, plasma cells, and immature dendritic cells; resistance to super antigen-induced T
cell death; and a requirement for lymphocytes during disease development.
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arthritis in certain genetic backgrounds.66) Similarly,
we found that HTLV-1 pX enhanced F759 arthritis in
a C57BL/6 background.67) Thus, the F759 mutation
enhanced STAT3 activation via IL-6, whereas
HTLV-1 pX activated NF-5B, suggesting that both
STAT3 and NF-5B are involved in F759 arthritis.
Using bone-marrow transplantation studies and
various knock-out mouse strains, we demonstrated
that F759 arthritis is CD4+ T cell–dependent, and
that the gp130 F759 mutation must be present in
nonhematopoietic cells, but not in immune cells. In
response to IL-6 stimulation, these nonhematopoietic
cells from F759 mice show enhanced production of
the T-cell survival factor IL-7, leading to the
activation of CD4+ T cells via homeostatic prolifer-
ation, an important step in the development of F759
arthritis (Fig. 10).19) Thus, our results demonstrate
that interactions between nonimmune tissues and the
immune system make critical contributions to auto-
immune F759 arthritis and suggest that nonimmune
systems may play a more general etiologic role in
autoimmune diseases.
Classiﬁcation of CD4+ T cells into T helper 1
(Th1) and Th2 cells has provided a framework for
understanding the contributions of various CD4+ T
cell subtypes to autoimmune diseases.68)–70) Further-
more, recent studies have identiﬁed Th17 cells as a
previously unknown arm of the CD4+ T cell eﬀector
response (Fig. 11). These cells secrete several proin-
ﬂammatory cytokines, including IL-17A, an impor-
tant cytokine in such autoimmune diseases as
collagen-induced arthritis, experimental autoimmune
encephalomyelitis (EAE), and the arthritis disorders
IL-6 family
cytokines
Dendritic 
Cells
IL-7
CD4+T cells 
STAT3
Nonimmune tissues Immune system
cytokines
IL-17, TNFα, IL-6 ...
F759 mutation
Fig. 10. Interactions between nonimmune tissues and the immune system play critical etiologic roles in autoimmune diseases. The F759
mutation in nonimmune cells, particularly in type 1 collagen+ ﬁbroblasts, induces excessive IL-7 production, followed by activation of
CD4+ T cells in the presence of dendritic cells. Activated CD4+ T cells express cytokines, including IL-17A, TNF-,, and IL-6, which
leads to the development of arthritis.
Th17
RORgT
Treg
Foxp3
IL-12
Inflammation
Autoimmune
Diseases
Th2
GATA-3
Th1
T-Bet
Repression of
Immune
Response
Allergy
Infection
Autoimmune
Diseases
IL-4
TGFβ + IL-6
TGFβ
IFNγ
IL-4
IL-17
IL-10
TGFβ
Fig. 11. IL-6 together with TGF- induces Th17 cell develop-
ment, a pivotal step in the development of autoimmune diseases
and inﬂammation.
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deﬁcient mice.71)–74) F759 arthritis is also dependent
on IL-17A.75) Another T cell subset, Treg cells, has
been shown to regulate immune responses, while
abnormalities in these cells cause autoimmune
diseases.76) Additionally, IL-6 together with TGF--
induces Th17 cell development, whereas TGF--
induces Treg cell development. Thus, IL-6 is a
key cytokine involved in T cell diﬀerentiation
(Fig. 11).30),31) We have shown that gp130 and
STAT3 in T cells are essential for Th17 develop-
ment.34) Taken together, these results indicate that
IL-6 makes signiﬁcant contributions to both normal
immune responses and autoimmune diseases.
Our research has also demonstrated that IL-6
not only induces IL-17A expression, but is also a
target gene for IL-17A in nonimmune cells like
ﬁbroblasts. Importantly, IL-6 is a critical down-
stream target gene for IL-17A in F759 arthritis. We
showed that IL-17A–induced NF-5B activation and
subsequent IL-6 gene expression are augmented in
the presence of IL-6. This synergistic induction of IL-
6 expression is mediated by an interaction between
NF-5B and STAT3. IL-6 then induces Th17 cells to
produce IL-17A, completing a positive feedback loop
in nonimmune cells. We have named this positive
loop the “IL-6 ampliﬁer” (Fig. 12).75) Of note, we
showed that the development of F759 autoimmune
arthritis requires the IL-6 ampliﬁer in type 1
collagen+ nonimmune tissues. The IL-6 ampliﬁer
plays a central role in the interactions between the
immune system and nonimmune tissues through the
activation of both NF-5B and STAT3. This signaling
ampliﬁer is activated in F759 mice, for example, in
which IL-6–mediated STAT3 activation is enhanced
by the lack of SOCS3-mediated negative feedback.
Also consistent with this idea, HTLV1-pX activates
NF-5B and enhances F759 arthritis. We also showed
that MOG-speciﬁc, Th17 cell–induced EAE is
dependent on STAT3 in type 1 collagen+ nonimmune
tissues.75) Collectively, these data led us to hypothe-
size that a number of diﬀerent events, including
antigen-speciﬁc T cell development, viral infection,
injury, and/or physical stimulation, are capable of
activating the IL-6 ampliﬁer through STAT3 and/or
NF-5B in nonimmune tissues, and thereby may
critically contribute to autoimmune diseases
(Fig. 13). In this scenario, tissue-speciﬁc autoimmune
disease could be triggered by not only tissue-speciﬁc
immune response but also any event that activates
STAT3 and/or NF-5B in the target tissue (e.g.,
activation of the IL-6 ampliﬁer).
Conclusions
Thirty-eight years ago, when I graduated from
the Osaka University Medical School, I could not
have imagined where this research would take me.
We discovered IL-6 is an essential multifunctional
cytokine involved not only in immune responses, but
also embryonic development, inﬂammation, and the
hematopoietic and nervous systems. We have now
begun to understand how autoimmune diseases such
as RA develop and the relationship with IL-6. For
example, dysregulation of IL-6 signaling induces
autoimmune arthritis in F759 mice; and we have
identiﬁed an IL-6 ampliﬁer, which critically contrib-
utes to F759 arthritis. Thus, it is possible that any
factor capable of chronically activating NF-5Ba n d /
or STAT3 in nonimmune tissues will precipitate RA,
a model that may be generally applicable to other
autoimmune diseases (Fig. 13). Therapeutically tar-
geting IL-6 receptors has been shown beneﬁcial for
many RA patients.16),17) Thus, our scientiﬁc research
during the last 30 years has helped elucidate the
immunological underpinnings of and laid the foun-
dation for a new biologic drug for RA and potentially
other autoimmune and inﬂammatory diseases.
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